Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
12 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
10
10 articles ont été cités au moins 10fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
580
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
29
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
11
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris Cité · Hôpital Cochin
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
World journal of surgery · 2019
AbstractBackgroundTo evaluate FCH‐PET/CT and parathyroid 4D‐CT so as to guide surgery in patients with primary hyperparathyroidism (pHPT) and prior neck surgery.MethodsMedical records of all patients referred for a FCH‐PET/CT in our institution were systematically reviewed. Only patients with pHPT, a history of neck surgery (for pHPT or another reason) and an indication of reoperation were included. All patients had parathyroid ultrasound (US) and Tc‐99m‐sestaMIBI scintigraphy, and furthermore, some patients had 4D‐CT. Gold standard was defined by pathological findings and/or US‐guided fine‐needle aspiration with PTH level measurement in the washing liquid.ResultsTwenty‐nine patients were included in this retrospective study. FCH‐PET/CT identified 34 abnormal foci including 19 ectopic localizations. 4D‐CT, performed in 20 patients, detected 11 abnormal glands at first reading and 6 more under FCH‐PET/CT guidance. US and Tc‐99m‐sestaMIBI found concordant foci in 8/29 patients. Gold standard was obtained for 32 abnormal FCH‐PET/CT foci in 27 patients. On a per‐lesion analysis, sensitivity, specificity, positive and negative predictive values were, respectively, 96%, 13%, 77% and 50% for FCH‐PET/CT, 75%, 40%, 80% and 33% for 4D‐CT. On a per‐patient analysis, sensitivity was 85% for FCH‐PET/CT and 63% for 4D‐CT. FCH‐PET/CT results made it possible to successfully remove an abnormal gland in 21 patients, including 12 with a negative or discordant US/Tc‐99m‐sestaMIBI scintigraphy result, with a global cure rate of 73%.ConclusionFCH‐PET/CT is a promising tool in the challenging population of reoperative patients with pHPT. Parathyroid 4D‐CT appears as a confirmatory imaging modality.
The European journal of surgery = Acta chirurgica · 2002
World journal of surgery · 2020
AbstractBackgroundPrimary hyperparathyroidism (HPT1) is the most frequent endocrinopathy in multiple endocrine neoplasia type 1 (MEN1). Its surgical management is challenging. We aimed to describe and compare the imaging findings of parathyroid ultrasound (US), sestaMIBI scintigraphy (sestaMIBI), and 18F‐fluorocholine (FCH) PET/CT in a series of MEN1 patients with HPT1.MethodsRetrospective analysis of a cohort of MEN1 patients with HPT1 assessed by parathyroid US, sestaMIBI scintigraphy and SPECT/CT, and FCH‐PET/CT for potential surgery between 2015 and 2019.ResultsTwenty‐two patients with a confirmed diagnosis of MEN1 who presented with HPT1 and were assessed by the 3 imaging modalities were included. After imaging workups, 11 patients were operated on for the first time, 4 underwent a redo surgery, and 7 did not undergo an operation. The overall patient‐based positivity rate of imaging was 91% (20 of 22) for parathyroid US and 96% (21 of 22) for both sestaMIBI and FCH‐PET/CT. The 3 imaging modalities demonstrated negative findings in 1/22 patient who did not undergo surgery. Overall, 3 pathologic glands were not detected by any imaging technique. SestaMIBI and FCH‐PET/CT both resulted in the same 3 false‐positive results in ectopic areas with a significant uptake on two thymic carcinoid tumors and one inflammatory lymph node. FCH‐PET/CT provided more surgically relevant data than sestaMIBI in 4/11 patients with initial surgery and in 1/4 patient who underwent redo surgery.ConclusionsCompared to sestaMIBI scintigraphy, FCH‐PET/CT provides additional information regarding the number of pathologic parathyroid glands and their localization in MEN1 patients with HPT1.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Annales d'endocrinologie · 2025 · Journal Article
Schubert L, Gaillard M, Melot C, Delbot T, et al.
The Journal of clinical endocrinology and metabolism · 2024 · Editorial
Koumakis E, Gauthé M, Martinino A, Sindayigaya R, et al.
The Journal of clinical endocrinology and metabolism · 2023 · Journal Article
Koumakis E, Gauthé M, Martinino A, Sindayigaya R, et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2023 · Journal Article
Talbot JN, Périé S, Tassart M, Delbot T, et al.
Diagnostic and interventional imaging · 2022 · Journal Article
Dudoignon D, Delbot T, Cottereau AS, Dechmi A, et al.
World journal of surgery · 2020 · Journal Article
Gauthé M, Dierick-Gallet A, Delbot T, Bricaire L, et al.
Clinical nuclear medicine · 2019 · Case Reports
Zhang-Yin J, Gaujoux S, Delbot T, Gauthé M, et al.
World journal of surgery · 2019 · Evaluation Study
Amadou C, Bera G, Ezziane M, Chami L, et al.
Annales d'endocrinologie · 2016 · Journal Article
Fui SL, Bonnichon P, Bonni N, Delbot T, et al.
The Journal of clinical endocrinology and metabolism · 2012 · Journal Article
Clerc J, Bienvenu-Perrard M, de Malleray CP, Dagousset F, et al.
European journal of internal medicine · 2005 · Journal Article
Pichon B, Lidove O, Delbot T, Aslangul E, et al.
The European journal of surgery = Acta chirurgica · 2002 · Journal Article
Leenhardt L, Menegaux F, Franc B, Delbot T, et al.